Keros Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for KROS, updated each market day.
KROS AI Sentiment
AI sees no strong directional signal for Keros Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: Sept. 16, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Keros Therapeutics, Inc. Common Stock
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Sector
Exchange
Market Cap
$221,469,689
Cap Tier
Employees
92
Headquarters
LEXINGTON, MA
Listed Since
April 8, 2020
Website
KROS Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
KROS Volatility
Keros Therapeutics, Inc. Common Stock has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
